After 20 Years of Watching Diabetes Tech, Kliff Eyes Smart Insulin Pens, CGM for Patients With Type 2 Diabetes
An experienced market watcher who has diabetes predicts the key to success will come down to one factor: ease of use.
Although current medications can maintain healthy blood sugar levels in most patients who have type 1 (T1D) or type 2 diabetes (T2D), most patients don’t use them correctly and therefore suffer the expensive and unpleasant complications of both hyper- and hypoglycemia. Less than half of all patients with T2D achieve glycemic goals advocated by the American Diabetes Association, and about two-thirds die prematurely of heart disease.1
Study results indicate that educational interventions can boost treatment adherence, at least among some patients,2 but many experts believe the only hope for widespread improvement among real-world patients lies in new medications and novel technologies—products that dramatically reduce the pain and complexity of proper self-care.
David Kliff, who has run Diabetes Investor since he was diagnosed with the condition more than 20 years ago, is a leading spokesman for this view. His livelihood depends upon being able to predict how patients will behave (and, therefore, what they will buy), and he scoffs at the notion that any affordable intervention produces significantly better outcomes with traditional treatment tools. He believes that better tools can produce better outcomes, that several significantly better tools have recently hit the market, and that more are coming soon.
Kliff is not alone in his general optimism, but his specific predications differ from those of many others who think technology is about to revolutionize Continue reading